1,032 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Merck's Keytruda Misses One of Two Goals in Lung Cancer Study http://www.zacks.com/stock/news/706462/mercks-keytruda-misses-one-of-two-goals-in-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-706462 Jan 07, 2020 - Merck's (MRK) phase III first-line SCLC study fails to meet one of the two primary endpoints. It signs an oncology collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals.
AstraZeneca's Lynparza Gets FDA Nod for Pancreatic Cancer http://www.zacks.com/stock/news/695998/astrazenecas-lynparza-gets-fda-nod-for-pancreatic-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-695998 Dec 31, 2019 - AstraZeneca (AZN) and Merck's Lynparza becomes the first PARP inhibitor to get approval for treating pancreatic cancer in the United States.
3 Dividend-Paying Large Cap Pharma Stocks to Consider for 2020 http://www.zacks.com/stock/news/690807/3-dividend-paying-large-cap-pharma-stocks-to-consider-for-2020?cid=CS-ZC-FT-stocks_in_the_news|investment_ideas-690807 Dec 27, 2019 - The stock market continued its end of the year rally Friday as the three major indices all hit new intraday highs.
ImmunoGen Lead Drug Gets Nod for Accelerated Approval Pathway (Revised) http://www.zacks.com/stock/news/685596/immunogen-lead-drug-gets-nod-for-accelerated-approval-pathway-revised?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-685596 Dec 24, 2019 - FDA approves a new pivotal study to support accelerated approval pathway for ImmunoGen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine.
AstraZeneca Gets FDA Nod for New Breast Cancer Drug Enhertu http://www.zacks.com/stock/news/684166/astrazeneca-gets-fda-nod-for-new-breast-cancer-drug-enhertu?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-684166 Dec 23, 2019 - AstraZeneca's (AZN) antibody drug conjugate candidate, Enhertu gets FDA approval for treating HER2-positive breast cancer in third or later-line setting.
Bristol-Myers' Revlimid Combo Gets EU Nod for New Indication http://www.zacks.com/stock/news/684137/bristol-myers-revlimid-combo-gets-eu-nod-for-new-indication?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-684137 Dec 23, 2019 - The EC approves Bristol-Myers' (BMY) Revlimid in combination with Rituxan for the treatment of previously-treated FL (Grade 1-3a).
3 Income Stocks to Buy with Market at New Highs http://www.zacks.com/stock/news/680533/3-income-stocks-to-buy-with-market-at-new-highs?cid=CS-ZC-FT-stocks_in_the_news|investment_ideas-680533 Dec 20, 2019 - The stock market rose to record highs again on Friday as part of a much longer and historic expansion in the US economy.
Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs http://www.zacks.com/stock/news/679924/pharma-stock-roundup-lillys-upbeat-2020-outlook-fda-nod-for-pfe-mrks-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-679924 Dec 20, 2019 - Lilly (LLY) issues upbeat financial guidance for 2020. FDA approves label expansion of Pfizer's (PFE) Xtandi and Merck's (MRK) Ebola vaccine, Ervebo.
Seattle Genetics Gets Speedy FDA Nod for Bladder Cancer Drug http://www.zacks.com/stock/news/678525/seattle-genetics-gets-speedy-fda-nod-for-bladder-cancer-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-678525 Dec 19, 2019 - The FDA grants accelerated nod to Seattle Genetics' (SGEN) Padcev to treat urothelial cancer. It also assigns Breakthrough Therapy tag to tucatinib for advanced/metastatic HER2-positive breast cancer.
Pentair Shuts Down Aquaculture Business, Divests Vaki Unit http://www.zacks.com/stock/news/678153/pentair-shuts-down-aquaculture-business-divests-vaki-unit?cid=CS-ZC-FT-analyst_blog|company_news_-_corporate_actions-678153 Dec 19, 2019 - Pentair (PNR) divests Vaki business unit to focus on the residential and commercial pool segments.

Pages: 1234567891011...104

<<<Page 6>